



Living Cell Technologies Limited

Suite 2.11 / 737 Burwood Rd

Hawthorn VIC 3122

ABN: 14 104 028 042

Leading US Neuroscientist appointed Chief Scientific Officer of Living Cell Technologies

ASX Announcement – 12 October, 2005, Melbourne, Australia:

Living Cell Technologies Limited (ASX: LCT) today announced that Dr Dwaine F. Emerich has been appointed **Chief Scientific Officer** of LCT BioPharma Inc.

Dr Emerich, a highly regarded and experienced scientist, has been with LCT's US operations as Vice-President of Research since 2003. He joined the company from Sertoli Technologies Inc where he led the company's research efforts to develop and commercialise Sertoli-based cell products.

"Dwaine's breadth and depth of experience in cell therapy research across strong US public and private companies offers LCT a significant competitive advantage in developing our products to meet critical market needs," said David Collinson, LCT's Chief Executive Officer.

Commenting on his appointment, Dr Emerich said:

"LCT's cell therapy technologies hold significant opportunities as we strive to treat Huntington's disease, insulin-dependent diabetes and haemophilia. I look forward to the exciting challenge of taking LCT's strategic research and development efforts further towards the marketplace."

Dr Emerich has been particularly instrumental in the development of LCT's NeurotrophinCell product. Choroid plexus cells are encapsulated in a clear bio-capsule derived from seaweed and transplanted into the region of the brain predominantly affected by Huntington's disease.

Prior to LCT, Dr Emerich was also Director of Biological Research for Alkermes Inc and CytoTherapeutics Inc. (now Stem Cells Inc. in Palo Alto, Ca.) Dr. Emerich has contributed to almost 200 scientific articles. He currently is a member of several scientific journal editorial boards and has lectured across the United States and Europe.

"I'm delighted that Dwaine has accepted this expanded role. He is an exceptional member of our team and highly regarded as a scientific leader in the field of cell transplantation and therapeutic delivery of proteins," Mr Collinson said.

"His appointment further strengthens LCT's experienced and dedicated management team as we move towards the beginning of phase I clinical trials."

Dr Emerich will work across LCT's US, NZ and Australian teams.

LCT is preparing US Food and Drug Administration (FDA) Investigational New Drug (IND) applications for phase 1 clinical trials for two portfolio products, NeurotrophinCell and DiabeCell.



Contacts:		
Peter De Luca Media +61 3 9813 5501	Paris Brooke General Manager – LCT (AUS) +61 3 9813 5501	Dr. Alfred Vasconcellos President and CEO (US) +1(401) 821-3500

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies Ltd (ASX: LCT) develop live cell therapy products to treat life threatening human diseases. The ASX listed, vertically integrated company operates globally through offices in Australia, New Zealand and the United States.

LCT focuses on developing treatments where healthy living cells are injected into patients to replace or repair damaged tissue, without requiring the use of toxic drugs to prevent rejection. The company's product portfolio focuses on treatments for people with Huntington's disease, insulin-dependent diabetes and haemophilia.